Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Janssen In-licenses CAR-Ts for $245 Million Upfront, its 2nd CAR-T Deal with a China Biotech

publication date: May 2, 2023

Janssen Biotech in-licensed CAR-T candidates from a China biotech, paying $245 million upfront to Cellular Biomedicine Group (CBMG) for global ex-China rights to two clinical stage CD20-targeting CAR-T candidates. One of the candidates has already started trials. In a China Phase I study, patients with non-Hodgkin's lymphoma, most of whom were diagnosed with diffuse large B-cell lymphoma (DLBCL), received a novel bispecific CAR-T therapy targeting both CD19 and CD20. A trial targeting CD20 alone will start later this year. In late 2017, Janssen acquired ex-China rights to a Legend Biotech that targets B38M for multiple myeloma, paying $350 million upfront. One year ago, the drug was approved in the US. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here